Sign in Subscribe
Drugs

Shire Pharmaceuticals' Alzheimer's Drug Hopes Emerge, Boosting Shares

Strategic Insights

— 1 min read

Shire Pharmaceuticals' newly developed Alzheimer's disease drug, made from daffodil bulbs in collaboration with Johnson & Johnson, is generating positive buzz among investors. The company's shares hit an all-time high on Friday, with analysts anticipating favorable results from the Amsterdam conference scheduled for this week. Shire's optimism about the drug has sparked hopes for a breakthrough in the sector, although this news is unlikely to assuage concerns in other small-cap drug stocks. Meanwhile, Vanguard Medica, a company with a new migraine drug nearing launch, continues to struggle despite its promising prospects.

Key Takeaways:

  • Shire Pharmaceuticals' new Alzheimer's disease drug, developed in collaboration with Johnson & Johnson, is expected to report results at an Amsterdam conference this week.
  • The company's shares reached an all-time high of 487.5p on Friday, reflecting investor optimism about the drug.
  • Analysts, including Lehman's Stewart Adkins, believe that Shire's invitation to analysts suggests a positive outlook for the company.
  • Vanguard Medica, which is poised to launch a new migraine drug, continues to struggle despite its promising prospects.
  • The company's shares slumped to an all-time low of 237.5p on Friday, reflecting a lack of confidence in the biotech sector.
  • British Biotech's shares remain at an all-time low, despite a significant investment by Morgan Stanley Securities and Boston investors Oechsle International.
  • The British Biotech fiasco has not deterred the formation of new biotech companies, including Synomics and ReGen Therapeutics.

Statistics:

  • Shire Pharmaceuticals' shares reached an all-time high of 487.5p on Friday.
  • Vanguard Medica's shares slumped to an all-time low of 237.5p on Friday.
  • British Biotech's shares have currently hovered at all-time lows.
  • Morgan Stanley Securities and Boston investors Oechsle International bought a combined 25.5 million British Biotech shares, or nearly 13% of the stock, in the last two weeks.
  • The US biotech sector is critical to the national interest, with Britain and Germany at the forefront of new biotech company formations.
  • The UK government has allocated over £1 billion to bolster Britain's science base, highlighting the sector's importance.

Sources:

  • "Money Perspectives", IOS & Bloomberg (no publication date provided)
  • "Shire on speed-up in Alzheimer's work", Joe Harland, Financial Times (no publication date provided)
  • "British Biotech Slumps On Queries Over Start-Up", Rachel Plenderleith, Reuters (no publication date provided)
  • "Biotech share slump", John Parkinson, Financial Times (no publication date provided)

Read more